Get the Stockscreener App
1.53
1.92%
-0.03
After Hours:
1.49
-0.04
-2.61%
MAIA Biotechnology Inc stock is traded at $1.53, with a volume of 988.81K.
It is down -1.92% in the last 24 hours and down -19.90% over the past month.
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.
See More
Previous Close:
$1.56
Open:
$1.57
24h Volume:
988.81K
Relative Volume:
0.90
Market Cap:
$56.66M
Revenue:
-
Net Income/Loss:
$-25.94M
P/E Ratio:
-1.1087
EPS:
-1.38
Net Cash Flow:
$-15.79M
1W Performance:
-29.82%
1M Performance:
-19.90%
6M Performance:
-0.65%
1Y Performance:
-8.38%
1-Day Range:
$1.485
$1.57
1-Week Range:
$1.41
$2.43
52-Week Range:
$0.87
$3.19
MAIA Biotechnology Inc Stock (MAIA) Company Profile
Name
MAIA Biotechnology Inc
Sector
Industry
Phone
312 416 8592
Address
444 West Lake Street, Suite 1700, Chicago
Compare MAIA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAIA
MAIA Biotechnology Inc
|
1.53 | 57.77M | 0 | -25.94M | -15.79M | -1.38 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
MAIA Biotechnology Inc Stock (MAIA) Latest News
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) - GlobeNewswire Inc.
Is the Market Bullish or Bearish on MAIA Biotechnology Inc? - Benzinga
MAIA Biotechnology Completes $30 Million Public Stock Offering - TipRanks
Maia Biotechnology Inc enters underwriting agreement with Konik Capital PartnersSEC filing - marketscreener.com
Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital PartnersSEC Filing - TradingView
MAIA Biotechnology Prices $30 Million Offering of 20 Million Shares at $1.50 - TradingView
MAIA Biotechnology (NYSE American: MAIA) closes $30M common stock raise - Stock Titan
Cancer drug developer MAIA raises $30M to fund new trials - Stock Titan
[424B5] MAIA Biotechnology, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
MAIA Shares Fall After Pricing of $30 Million Public Offering - marketscreener.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
MAIA Biotechnology shares drop 29% on discounted stock offering By Investing.com - Investing.com Canada
Cancer immunotherapy firm MAIA raises $30M for trials, costs - Stock Titan
MAIA Biotechnology Prices $30 Mln Public Offering Of Shares At $1.50/shr; Stock Down - Nasdaq
MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock - ChartMill
MAIA Biotechnology (NYSE: MAIA) offers common stock and pre-funded warrants - Stock Titan
Cancer immunotherapy developer MAIA plans stock sale to fund trials - Stock Titan
MAIA Should I Buy - Intellectia AI
MAIAMAIA Biotechnology Inc. Latest Stock News & Market Updates - Stock Titan
MAIA Biotechnology Highlights Progress in Phase 3 Oncology Program - TipRanks
MAIA Biotechnology cites Phase 3 momentum for ateganosine, targets $50B immunotherapy market - TradingView
MAIA Biotechnology (NYSE: MAIA) touts Phase 3 NSCLC drug and Fast Track - Stock Titan
MAIA Biotechnology : Shareholder Letter - marketscreener.com
MAIA Biotechnology's Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market - 富途牛牛
New lung cancer drug targets 50,000 patients with no standard care - Stock Titan
Portfolio Update: Can MAIA Biotechnology Inc grow without dilutionJuly 2025 Earnings & Weekly High Potential Stock Alerts - baoquankhu1.vn
MAIA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
MACD Signal: How does Franklin Wireless Corp perform in inflationary periodsPortfolio Value Report & Fast Entry Momentum Alerts - baoquankhu1.vn
Quarterly Recap: What is the next catalyst for MAIA Biotechnology IncGlobal Markets & Accurate Buy Signal Alerts - baoquankhu1.vn
MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Sees Significant Growth in Short Interest - MarketBeat
Whale Trades: How do insiders feel about MAIA Biotechnology IncWeekly Profit Analysis & Verified Technical Signals - baoquankhu1.vn
Weekly Recap: What is the next catalyst for MAIA Biotechnology IncMarket Growth Review & Long-Term Safe Return Strategies - baoquankhu1.vn
MAIA’s New Agreement With Big Pharma Roche Turns Retail Investors Bullish As Stock Soars - MSN
Why MAIA Biotechnology Inc. stock could benefit from AI revolution2025 Trading Volume Trends & Stepwise Trade Execution Plans - mfd.ru
MAIA Technical Analysis & Stock Price Forecast - Intellectia AI
Does MAIA Biotechnology Inc. have pricing power2025 Performance Recap & Low Risk High Win Rate Picks - mfd.ru
What’s the MACD signal for MAIA Biotechnology Inc.2025 Macro Impact & Low Risk High Win Rate Stock Picks - mfd.ru
Is MAIA Biotechnology Inc. showing insider buying2025 EndofYear Setup & Weekly High Return Forecasts - mfd.ru
Is MAIA Biotechnology Inc. stock showing strong momentumGDP Growth & Real-Time Sentiment Analysis - mfd.ru
What are the future prospects of MAIA Biotechnology IncSwing Trade & Daily Technical Forecast Reports - baoquankhu1.vn
MAIA Biotechnology (NYSEAMERICAN:MAIA) Shares Up 0.5%Should You Buy? - MarketBeat
MAIA Biotechnology (NYSEAMERICAN:MAIA) Shares Up 0.5% – Should You Buy? - Defense World
Why MAIA Biotechnology Inc. stock is popular among millennialsPortfolio Value Summary & Daily Growth Stock Investment Tips - mfd.ru
Fed Watch: Will MAIA Biotechnology Inc outperform small cap indexes2025 Market Sentiment & Safe Investment Capital Preservation Plans - baoquankhu1.vn
MAIA Biotechnology announces significant insider buying - MSN
Risk Analysis: Is Roblox Corporation stock risky to hold now2025 Year in Review & High Accuracy Investment Signals - baoquankhu1.vn
$207B Market Shift: The Race for Fast Track Approval in Oncology (2026-02-05) - Seeking Alpha
$207B Market Shift: The Race for Fast Track Approval in Oncology - Sahm
Geopolitics Watch: What are the future prospects of MAIA Biotechnology IncTrade Analysis Summary & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment - The Globe and Mail
Late-Stage Breakthroughs: How 2026’s Top Clinical Platforms Are Redefining Cancer Treatment - Cantech Letter
MAIA Biotechnology Inc Stock (MAIA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Cap:
|
Volume (24h):